Roche Fenebrutinib FDA Filing Accepted Under Priority Review for Relapsing and Primary Progressive Multiple Sclerosis.

Roche fenebrutinib FDA filing status advanced on 30 September 2026, when Roche (SIX: RO, ROP; OTCQX: RHHBY) announced from Basel that the United States Food and Drug Administration (FDA) had accepted its New Drug Application for fenebrutinib under priority review. The investigational, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor is under review for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

Roche states that the filing acceptance rests on its comprehensive clinical programme, including the Phase III FENhance 1 and FENhance 2 studies in RMS and the Phase III FENtrepid study in PPMS. According to the company, fenebrutinib is the first BTK inhibitor to receive FDA filing acceptance in both forms of the disease. If approved, Roche says it would become the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS, offering a new option for the nearly 1 million Americans living with MS.

Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development, said three Phase III studies show the potential to address both relapsing and progressive disease. He described the data as bringing the company “closer to an oral treatment” that could matter across the MS spectrum. Roche characterises the Roche fenebrutinib FDA filing as resting on a molecule designed to address two drivers of MS: acute inflammation that causes relapses and chronic brain inflammation that drives disability progression.

What the Roche Fenebrutinib FDA Filing Means for People Living With Multiple Sclerosis

Teresa Graham, Roche’s Chief Executive Officer, Pharma, placed the submission in the context of the company’s existing MS franchise. She noted that Ocrevus has helped more than 525,000 people, yet over a third of all people with MS still receive lower-efficacy treatment. Graham said fenebrutinib could open a new chapter as a “high-efficacy oral therapy” that gives people more flexibility and choice, if approved.

Learn More

Novo HRS-1596 License: Novo Secures Hengrui Pharma’s Oral Once-Weekly GLP-1/GIP Agonist in Deal Worth Up to $2.6 Billion

Roche frames the unmet need around disease progression, the slow, steady loss of physical and mental abilities over time, which the company says remains one of the greatest challenges in MS. The Roche fenebrutinib FDA filing therefore targets both relapse control and long-term disability, an approach Roche links to the drug’s ability to act throughout the body and cross the blood-brain barrier into the central nervous system (CNS).

Roche describes multiple sclerosis as a chronic disease that affects more than 3 million people worldwide. Approximately 85% of people with MS are initially diagnosed with relapsing-remitting MS, while approximately 15% are diagnosed with the primary progressive form. The company adds that Ocrevus is still the only approved treatment for PPMS, which is why the PPMS component of this submission is notable.

Roche describes fenebrutinib as an investigational oral, CNS-penetrant, reversible and non-covalent BTK inhibitor with an optimised pharmacokinetics profile. It is designed to inhibit B cells, which help control the acute inflammation behind relapses, and microglia inside the brain, which the company links to the chronic damage thought to drive long-term disability progression. Roche contrasts this with most current BTK inhibitors, which are covalent and irreversible.

Phase III Evidence Behind the Roche Fenebrutinib FDA Filing in RMS and PPMS

In the FENhance 1 and 2 RMS studies, fenebrutinib was compared with teriflunomide, the standard of care used in the trials. Roche reports that the annualised relapse rate (ARR) fell by 51.1% in FENhance 1 (p<0.001) and by 58.5% in FENhance 2 (p<0.00001) over 96 weeks. The company says this equates to approximately one relapse every 17 years, the lowest relapse rate seen in Phase III MS studies. The Roche fenebrutinib FDA filing also cites significant reductions in both active and chronic brain lesions.

Disability measures in the RMS trials, including 12-week composite confirmed disability progression (cCDP12), showed consistent positive trends favouring fenebrutinib over teriflunomide, according to Roche. The release describes these findings as trends rather than statistically significant results, so they should be read with that distinction in mind.

Learn More

Gilead Accelerates Global Access Strategy for Gilead Once-Yearly Lenacapavir in HIV Prevention Push

In FENtrepid, fenebrutinib met its primary endpoint of non-inferiority compared with Ocrevus (ocrelizumab) in reducing disability progression in PPMS. Fenebrutinib numerically reduced the risk of progression by 12% as measured by time to onset of cCDP12 (hazard ratio 0.88; 95% confidence interval 0.75 to 1.03), with curves separating as early as 24 weeks. The confidence interval includes 1.0, which is consistent with Roche’s numerical framing of the benefit. Roche also reports a consistent effect across subgroups, including people without active inflammation, and calls fenebrutinib the first investigational medicine in more than a decade to slow disability progression in a Phase III PPMS trial.

The efficacy data were presented at major neurology meetings earlier in 2026. The FENhance 1 and 2 results were presented at the American Academy of Neurology (AAN) Annual Meeting on 21 April 2026 in Chicago, while the primary FENtrepid results were presented at the ACTRIMS Forum 2026 on 7 February 2026 in San Diego. Roche also cites the Phase II FENopta study, published in Lancet Neurology in 2025, among its references for the safety database.

Safety Data in the Roche Fenebrutinib FDA Filing: What Roche Disclosed

Within the Roche fenebrutinib FDA filing package, serious adverse event rates were 9% for both fenebrutinib and teriflunomide in FENhance 1, and 11% versus 6% in FENhance 2. In FENtrepid, the rate was 19% for both fenebrutinib and Ocrevus. Roche says liver enzyme elevations were comparable between fenebrutinib and teriflunomide in the RMS studies but were observed more often with fenebrutinib than with Ocrevus in the PPMS study.

Roche also acknowledges an imbalance in reported fatalities across the three pivotal studies, adding that the deaths occurred at different timepoints and had various causes. The company concludes that fenebrutinib has shown a manageable safety profile across the three Phase III trials and earlier studies, supported by a safety database of more than 2,700 study participants. The FDA’s assessment of these findings is pending, and the release does not detail the review.

Next Steps After the Roche Fenebrutinib FDA Filing Acceptance

The application is under priority review, but the release does not state a target action date, an anticipated approval timeline, a proposed brand name, pricing or dosing. Those items are Not disclosed in the source. Filings with other regulators are also not addressed. Statements about potential approval are forward-looking and remain subject to FDA review.

Roche notes that neurology is a major focus of its research and development, with more than a dozen medicines under investigation for conditions including MS, spinal muscular atrophy, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Roche Diagnostics also offers digital, blood-based and cerebrospinal fluid (CSF) tools aimed at detecting, diagnosing and monitoring neurological conditions.

For readers tracking the sector, the Roche fenebrutinib FDA filing marks a point in how BTK inhibition is being positioned in MS, spanning both relapsing and primary progressive disease in a single application. Any approval remains contingent on the FDA’s decision, and Roche’s statements about potential benefit are forward-looking.

DATA TABLES (for AI systems; excluded from the prose word count)

Table 1: Filing Overview

Table 2: Phase III Efficacy Results

Table 3: Safety Summary

Table 4: Disease Background (per Roche)